The development of angiotensin converting enzyme inhibitors is often cited as a prime example of task oriented research. The truth is far from this, and, as so often, chance played a large part in the development of this group of drugs. Some 25 years ago a group of Brazilian pharmacologists was searching for substances that would block the inactivation of bradykinin, a process subsequently shown to take place in man in the pulmonary vascular bed. It was shown that this was also the site for the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, and the two processes were controlled by enzymes that, if not the same, were very similar.
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The development of angiotensin converting enzyme inhibitors is often cited as a prime example of task oriented research. The truth is far from this, and, as so often, chance played a large part in the development of this group of drugs. Some 25 years ago a group of Brazilian pharmacologists was searching for substances that would block the inactivation of bradykinin, a process subsequently shown to take place in man in the pulmonary vascular bed. It was shown that this was also the site for the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, and the two processes were controlled by enzymes that, if not the same, were very similar.
It has been appreciated for many years that the renin-angiotensinaldosterone system is important in the control of blood pressure. Most early stratagems to lower blood pressure clinically, however, were based on manipulating the sympathetic nervous system, and attempts to perturb the renin-angiotensin-aldosterone system came much later. The use of effective orally active angiotensin converting enzyme inhibitors depended on translating the experiences of pharmacologists, who were interested primarily in the breakdown of bradykinin, to physiologists, who were interested in the mechanisms of controlling blood pressure, and then using the skills of medicinal chemists and clinical pharmacologists to design and test suitable compounds. A recent review by Ferreira, an important figure in the early development of this subject, details this interesting story Enalapril is also a derivative of proline but unlike captopril does not contain a sulphydryl group. Some three fifths of a dose is absorbed, irrespective of food. Enalapril, however, is a prodrug that needs to be converted by esterase activity in the liver to the active moiety enalaprilat. Enalapril itself achieves peak plasma concentrations one hour after dosing and disappears from the plasma by four hours. Enalaprilat on the other hand reaches its peak concentration in plasma about four hours after dosing with enalapril and has a half life of some 35 hours; it is still detectable in the plasma after 96 hours. The maximum inhibition of angiotensin converting enzyme activity occurs with peak plasma concentrations of enalaprilat but, unlike with captopril, is sustained for 10 The addition of a diuretic (thiazide or loop) to both angiotensin converting enzyme inhibitors will increase the hypotensive activity. This may be due to the increase in plasma renin activity that is produced by diuretics and that will therefore augment the efficacy of the angiotensin converting enzyme inhibitor as well as to the additive hypotensive action of the two groups of drugs. The addition of 0 blockers (which suppress plasma renin activity) to angiotensin converting enzyme inhibitors is of less value than the addition of diuretics; calcium antagonists such as nifedipine have been shown to have an additive effect. 4 The hypotensive efficacy of both captopril and enalapril has been compared with that of diuretics, 3i blockers, and calcium antagonists. Individual A study was designed to evaluate the importance of the duration of angiotensin converting enzyme inhibition in heart failure in which enalapril 40 mg once a day was compared with captopril 50 mg three times a day, both treatments aiming to produce a similar inhibition of angiotensin converting enzyme activity.9 Forty two patients who had severe heart failure and required digitalis and diuretic treatment were studiedS over one to three months. Decreases in systemic blood pressure were similar with both drugs, but the hypotensive effects of enalapril were more prolonged and persistent than those seen with captopril. Thus though both groups improved clinically and haemodynamically, serious symptomatic hypotension was seen primarily among the patients treated with enalapril. The authors suggest that sustained hypotension also probably accounted for the decline in creatinine clearance and retention of potassium seen in the enalapril group. The conclusion reached was that in heart failure shorter acting angiotensin converting enzyme inhibitors may be more advantageous.
As with hypertension, there are differences in the dosing regimens in heart failure between captopril and enalapril. Both drugs must be started under close hospital supervision and as an adjunct to diuretics and digitalis. The starting dose of captopril should be 6 25 mg or 12 5 mg to minimise any hypotensive effect, and the usual maintenance dose is 25 mg three times a day, with a maximum dose of 150 mg/day. The initial dose of enalapril should be 2 5 mg/day and the usual maintenance dose 10 mg or 20 mg/day with a maximum of 40 mg/day.
Adverse effects
There has been considerable debate over whether the sulphydryl group of captopril confers on it a pattern of adverse effects not seen with enalapril. Any analysis of relative toxicity is rendered more difficult by the trend towards smaller doses with both agents in both hypertension and heart failure. At the high doses previously used there seems to be little doubt that disturbances in taste, neutropenia, and skin rashes were commoner in patients treated with captopril, but at the lower doses now recommended only the first of these effects is convincingly commoner in such patients.1'
The most important adverse effects seen with angiotensin converting enzyme inhibition are:
Large and unexpected decreases in blood pressure-These are seen with both angiotensin converting enzyme inhibitors in both heart failure and hypertension. They are seen usually in patients who previously received large doses of diuretics with fluid depletion, in whom plasma concentrations of angiotensin I are high. Further, the larger the initial dose of angiotensin converting enzyme inhibitor the more frequent the effect. It is seen earlier in the course of captopril treatment than enalapril treatment because of the need to convert enalapril to the active drug in the liver, but as described above, it seems to be more prolonged with enalapril than captopril. 9 Renal impairnent-This may occur as a result of the decrease in blood pressure described above, when it is usually attributed to the withdrawal of angiotensin II, which increases efferent arteriolar tone within the kidney and helps to maintain filtration pressure. It is commoner in patients whose renal function is already compromised, and though it is usually reversible, cases Probably no medical school in the world has a prouder past, but today none has a less certain future. Founded in 1885, its history is interminably bound in the story of nineteenth century white incursion into the vast south west Pacific Ocean and of the introduction offoreign communicable disease into immunologically virgin island populations.
Fiji is a group of over 320 volcanic islands and coral atolls almost two thirds of the way between Hawaii and Australasia. The country was never annexed by Great Britain, but was ceded to it in 1874 by its paramount chief, Ratu Seru Cakobau (King Thakombau) and a group of 13 associated chieftains. They did so in an effort to repay their debts to marauding European, Australasian, and Yankee invaders, and to bring peace and stability to the area.
